Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders
用于治疗神经系统疾病的靶向药物递送的多聚肽共聚物制剂
基本信息
- 批准号:10617204
- 负责人:
- 金额:$ 36.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffinityAgeAgingAmino Acid SubstitutionAmino AcidsAmyotrophic Lateral SclerosisAntibodiesAutonomic DysfunctionAutonomic nervous systemAvidinAvidityBacteriophagesBindingBinding ProteinsBiodistributionBiologicalBiological AvailabilityBiological ProductsBloodBlood - brain barrier anatomyBrainBrain-Derived Neurotrophic FactorCatalogsCellsCentral Nervous SystemCentral Nervous System AgentsCentral Nervous System DiseasesCessation of lifeClinicCoupledCustomCyclizationDataDevelopmentDiagnosisDigestionDiseaseDisease ProgressionDoseDrug Delivery SystemsDrug ModelingsDrug TargetingEndotheliumEngineeringEquus caballusFormulationGelGoalsHistologicHomologous GeneHumanIn VitroIndividualIntramuscular InjectionsIntraperitoneal InjectionsLigandsMass Spectrum AnalysisMediatingMetabolismMethodologyMethodsModelingModificationMolecular StructureMonitorMotor NeuronsMusMuscular AtrophyNerve DegenerationNerve Growth FactorsNeuromuscular DiseasesNeuronsOrganPathway interactionsPatientsPenetrancePeptide HydrolasesPeptide SynthesisPeptidesPeripheralPersonsPharmaceutical PreparationsPolymersPreclinical TestingProteinsRabies virusResearchResistanceSerumSpinal CordStructureTherapeuticTissuesToxic effectTranslatingTranslationsUnited StatesVirus Diseasesagedamyotrophic lateral sclerosis therapyblood-brain barrier disruptionclinical translationcopolymerdesignglial cell-line derived neurotrophic factorimprovedin vivoinduced pluripotent stem celllipophilicitymacromoleculemouse modelnervous system disorderneuralneurotrophic factornew technologynext generation sequencingnon-invasive systemnovelnovel therapeuticspeptide structurepolymerizationpre-clinical researchprematurereceptorreceptor bindingscaffoldsciatic nerveside effectsuccesssystemic barriertargeted deliverytargeted treatmenttherapeutic developmenttherapeutically effectivetranscytosistranslational therapeuticsuptake
项目摘要
Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat
Nervous System Disorders
Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease that leads to
progressive muscle wasting, autonomic dysfunction and death within 5 years of
diagnosis, and each year >16,000 people are diagnosed. As research has made
tremendous strides in understanding the cellular mechanisms that underlie disease
progression, pre-clinical research has demonstrated the potential of nerve growth factor
(NGF), glial derived and neural derived neurotrophic factor (GDNF and BDNF), and
targeted biologics to halt disease progression. However, the clinical translation of
therapeutics to treat ALS and other nervous system disorders has lagged due to
complications associated with systemic administration or transient blood-brain barrier
damage. By using a bacteriophage biopanning strategy to perform an affinity based
screen, we aim to exploit a CNS entry pathway similar to rabies virus infection to
circumvent the barriers of systemic delivery and target therapeutics to neurons directly.
Thus, we propose to identify novel targeting peptides and biologics delivery strategies to
treat nervous system diseases. By using a bacteriophage biopanning strategy to perform
an affinity based screen, we have recently identified a peptide motif, TAxI, that mediates
uptake and delivery of a biologically active protein to the CNS after intramuscular
injection. Here, we demonstrate the ability of CNS targeting-peptides to deliver a model
drug into the CNS after IP injection. We propose to evaluate how aging and disease
progression impacts targeted drug delivery to the CNS with the goal of designing and
synthesizing materials for pre-clinical testing in a model of ALS. In this proposal, we
build upon TAxI by developing copolymer materials and a human TAxI-peptide for
translatable CNS delivery formulations to deliver biologics into the diseased CNS non-
invasively.
用于治疗的靶向药物的多聚肽共聚合制剂
神经系统疾病
肌萎缩性外侧硬化症(ALS)是一种毁灭性的神经肌肉疾病,导致
渐进的肌肉浪费,自主神经功能障碍和死亡在5年内
诊断,每年> 16,000人被诊断。随着研究的发展
在理解疾病基础的细胞机制方面的巨大进展
进展,临床前研究证明了神经生长因子的潜力
(NGF),神经胶质和神经衍生的神经营养因子(GDNF和BDNF),以及
有针对性的生物制剂阻止疾病进展。但是,
由于治疗ALS和其他神经系统疾病的治疗剂
与全身给药或瞬时血脑屏障相关的并发症
损害。通过使用噬菌体生物扫描策略来执行基于亲和力
屏幕,我们旨在利用类似于狂犬病病毒感染的CNS进入途径
直接将全身性传递的障碍和靶向治疗剂直接靶向神经元。
因此,我们建议确定新颖的靶向肽和生物制剂交付策略
治疗神经系统疾病。通过使用噬菌体生物封装策略来执行
一个基于亲和力的屏幕,我们最近确定了一个肽图案,即介导的肽图案
肌肉内摄取和递送生物活性蛋白向中枢神经系统
注射。在这里,我们证明了CNS靶向肽提供模型的能力
注射IP后,药物进入中枢神经系统。我们建议评估衰老和疾病如何
进展会影响针对中枢神经系统的药物的目标,以设计和
在ALS模型中合成用于临床前测试的材料。在这个建议中,我们
通过开发共聚物材料和人类的出租车肽来建立出租车
可翻译的中枢神经系统递送配方将生物制剂递送到患病的CNS非 -
侵入性。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and characterization of anionic poly(cyclopentadienylene vinylene) and its use in conductive hydrogels.
- DOI:10.1002/anie.202004098
- 发表时间:2020-05
- 期刊:
- 影响因子:0
- 作者:Daniel C. Lee;D. Sellers;Fan Liu;Andrew J Boydston;S. Pun
- 通讯作者:Daniel C. Lee;D. Sellers;Fan Liu;Andrew J Boydston;S. Pun
TAxI-peptide targeted Cas12a ribonuclease protein nanoformulations increase genome editing in hippocampal neurons.
- DOI:10.1016/j.jconrel.2022.12.057
- 发表时间:2022-12
- 期刊:
- 影响因子:0
- 作者:D. Sellers;Kunwoo Lee;N. Murthy;S. Pun
- 通讯作者:D. Sellers;Kunwoo Lee;N. Murthy;S. Pun
Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection.
- DOI:10.1002/anie.202107730
- 发表时间:2021-09-20
- 期刊:
- 影响因子:0
- 作者:Kacherovsky N;Yang LF;Dang HV;Cheng EL;Cardle II;Walls AC;McCallum M;Sellers DL;DiMaio F;Salipante SJ;Corti D;Veesler D;Pun SH
- 通讯作者:Pun SH
Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting.
优化了用于肿瘤靶向的 αvβ6 整合素结合肽的血清稳定性和特异性。
- DOI:10.1016/j.jbc.2021.100657
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Cardle II;Jensen MC;Pun SH;Sellers DL
- 通讯作者:Sellers DL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Drew L Sellers其他文献
Drew L Sellers的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Drew L Sellers', 18)}}的其他基金
Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders
用于治疗神经系统疾病的靶向药物递送的多聚肽共聚物制剂
- 批准号:
10400872 - 财政年份:2020
- 资助金额:
$ 36.54万 - 项目类别:
Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders
用于治疗神经系统疾病的靶向药物递送的多聚肽共聚物制剂
- 批准号:
10029634 - 财政年份:2020
- 资助金额:
$ 36.54万 - 项目类别:
Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders
用于治疗神经系统疾病的靶向药物递送的多聚肽共聚物制剂
- 批准号:
10178139 - 财政年份:2020
- 资助金额:
$ 36.54万 - 项目类别:
Targeting Ligands for autonomic uptake and drug delivery to the brain and spinal cord
自主摄取和药物递送至大脑和脊髓的靶向配体
- 批准号:
9385694 - 财政年份:2017
- 资助金额:
$ 36.54万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
- 批准号:
10726508 - 财政年份:2023
- 资助金额:
$ 36.54万 - 项目类别:
Anti-medin immunotherapy for vascular aging and related dementias
针对血管老化和相关痴呆的抗 Medin 免疫疗法
- 批准号:
10724869 - 财政年份:2023
- 资助金额:
$ 36.54万 - 项目类别:
Tissue-engineered Aged B Cell Immune Organoid to Study Antibody Secreting Cell Differentiation Trajectory
组织工程老化 B 细胞免疫类器官用于研究抗体分泌细胞分化轨迹
- 批准号:
10804886 - 财政年份:2023
- 资助金额:
$ 36.54万 - 项目类别:
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
CD98hc 脑穿梭机为阿尔茨海默病提供现成的神经保护抗体
- 批准号:
10566062 - 财政年份:2023
- 资助金额:
$ 36.54万 - 项目类别:
Developing therapeutic antibodies for Alzheimer's disease
开发阿尔茨海默病的治疗抗体
- 批准号:
10821560 - 财政年份:2023
- 资助金额:
$ 36.54万 - 项目类别: